Overview
FDC Limited is a leading pharmaceutical company in India, engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs). It is particularly noted for its expertise in oral rehydration solutions, energy drinks, antibiotics, and ophthalmic therapies.
The company has expanded its global footprint through two wholly-owned subsidiaries in the USA and UK, and a joint venture in South Africa. FDC is also setting up advanced manufacturing plants to enhance its production capabilities.
FDC has a strategic focus on innovation with ongoing projects like recombinant Granulocyte Colony Stimulating Factor and third-generation thrombolytes. It has received multiple regulatory approvals, including those from the US FDA and European agencies.
The company has executed multiple buybacks and mergers to optimize its equity structure, with significant acquisitions in South Africa, making Fair Deal Corporation Pharmaceutical SA (Pty) Ltd a subsidiary.
In recent years, FDC has diversified its nutraceuticals products, launching multiple energy and immunity-boosting drinks, aligning with modern health and wellness trends. New product launches and expansion into emerging markets continue to drive growth.
- Sector
Pharmaceuticals & Biotechnology
- Industry
Pharmaceuticals
- Market Cap
6,307 Cr
- Volatility
Low Risk
- P/E Ratio
22.4
- Industry P/E
34.1
- PEG Ratio
2.7
- P/B Ratio
2.5
- 52W High
528.30
- 52W Low
314.75
Financial Ratios
Sales CAGR
- 1Y
- 8.50%
- 3Y
- 10.87%
- 5Y
- 9.23%
- 10Y
- 8.30%
Profit CAGR
- 1Y
- -12.55%
- 3Y
- 7.60%
- 5Y
- 2.09%
- 10Y
- 5.51%
ROE
- TTM
- 11.32%
- 3Y
- 12.05%
- 5Y
- 12.77%
- 10Y
- 13.34%
ROCE
- TTM
- 15.18%
- 3Y
- 15.65%
- 5Y
- 16.59%
- 10Y
- 17.63%
Actions
AI Mode
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Ask AI
